Market ExpansionMRNA announced the company was awarded a tender from the European Commission for supply of its COVID vaccine in the EU, Norway and Macedonia.
Partnerships And CollaborationsThere are pipeline levers that could contribute to the top line in the medium-term, notably the MRK-partnered individualized neoantigen therapy, which has generated positive data to date.
Product ApprovalsThe company highlighted its expectation of receiving approvals for three products, including a next-gen COVID-19 vaccine and an RSV vaccine for high-risk adults.